Upstream Bio (UPB) Financials

Upstream Bio (NASDAQ: UPB) is still in a classic biotech “cash burn, no profitability yet” phase. The company generated modest quarterly revenue, but operating losses remain very large relative to sales. The most important story in the latest quarter is balance-sheet strength: Upstream Bio ended Q1 2026 with a substantial cash and investment position, which gives it runway to keep funding research and development.

What stands out most from the last several quarters:

• Strong liquidity cushion. As of Q1 2026, Upstream Bio held $96.7 million in cash and equivalents plus $197.9 million in short-term investments, or about $294.6 million in liquid resources.
• Large current asset base. Total current assets were $316.3 million in Q1 2026, far above total current liabilities of $13.7 million, suggesting no near-term balance-sheet stress.
• Operating cash burn improved sharply year over year. Net cash used in operating activities was $47.9 million in Q1 2026 versus $41.2 million in Q1 2025, but the company also had periods in 2025 with even heavier burn; the overall trend is still pre-commercial, but liquidity remains solid.
• Interest and investment income helps offset losses. Q1 2026 included $3.1 million of interest and investment income, which partially cushioned the operating loss.
• Shares outstanding stayed fairly stable. Basic weighted average shares were 54.3 million in Q1 2026, close to prior quarters, with no obvious sign of major dilution in the latest period.
• Revenue remains small and likely non-core. Q1 2026 revenue was $1.0 million, up from $668,000 in Q4 2025 and $566,000 in Q1 2025, but it is still tiny compared with expenses.
• R&D spending remains the main expense driver. Research and development was $36.6 million in Q1 2026, down from $40.2 million in Q4 2025 but still the largest cost line by far.
• Cash flow benefited from investment activity. Q1 2026 saw $42.4 million of net cash from investing activities, driven by maturities/sales of investments, which can help manage quarterly liquidity but is not recurring operating cash flow.
• Losses remain very large. Q1 2026 net loss was $40.6 million, only slightly better than the $42.5 million loss in Q4 2025.
• Operating losses are persistent. Q1 2026 operating loss was $43.6 million, reflecting a business that is still far from break-even.

Trend analysis over the last four years: Upstream Bio has consistently operated at a loss, with quarterly net losses generally ranging from about $11 million to $42 million. The company’s operating revenue has remained minimal and fairly stable, while R&D spending has increased and then remained elevated as the business advances its pipeline. That is typical for a development-stage biotech company, but it also means the stock’s long-term value will depend heavily on clinical progress, financing needs, and future commercialization potential rather than current earnings power.

Balance sheet trend: The company’s cash position has fluctuated materially from quarter to quarter, largely because of financing and investment activity. Even so, the latest quarter shows a strong liquid asset base and low current liabilities, which is a meaningful positive for investors because it reduces immediate refinancing risk. Equity has also remained large on paper, though retained earnings are deeply negative, reflecting cumulative losses.

Bottom line: Upstream Bio looks financially stable in the near term because of its cash and investment holdings, but the underlying business is still in heavy development mode. For retail investors, the key question is not current profitability — it is whether the company can advance its programs enough to justify the ongoing burn rate before needing to raise more capital.